Firefly Neuroscience, an AI-driven electroencephalography (EEG) platform that began trading on the Nasdaq Capital Market in August 2024, delivered a second-quarter print on August 11, 2026 that reads more like a clinical-stage biotech than a commercial medical-device company: revenue of $514 thousand, up 72 percent year over year, against a net loss of $1.98 million, with $9.2 million of cash, a $115.6 million accumulated deficit, and an explicit going-concern warning from management. The thesis is that the April 2025 acquisition of Evoke Neuroscience is converting Firefly from a research asset into a recurring-revenue EEG subscription business - Q2 2026 was the first full quarter of consolidated Evoke results - but the company is funding that transition with a pace of equity issuance that has already pushed the share count from 8.1 million at the start of 2025 to 15.7 million at the August cover date.
The mechanism that matters is the Firefly Flywheel, the management term for the loop in which every clinic that installs the FDA-cleared Evoke EEG System feeds standardized EEG and event-related-potential data into the company's analytics engine, expanding the proprietary database that, in turn, improves the AI model that draws clinicians to the platform in the first place. Q2 2026 showed the loop beginning to spin: subscription revenue alone reached $243 thousand in the quarter, more than the prior-year period's entire product-and-service line, and management reports 85-plus clinical sites in active use. The equity re-rates only if subscription revenue keeps compounding while the cost of capital stays bearable; the March and April 2026 private placements issued units at $1.50 alongside five-year warrants struck at $1.88 and $2.50, leaving 14.6 million warrants outstanding at a weighted average exercise price of $2.84 - a build-up of paper dilution that protects the cash balance but penalizes any equity holder below those strikes.
The single load-bearing risk is the going-concern question itself, which the company's independent auditors reiterated for the year ended December 31, 2025 and which management again flagged in the Q2 footnote. With a 12-month operating cash burn now running at roughly $7.4 million annualized off the H1 2026 print, and with the $7.4 million at-the-market facility undrawn as of June 30, 2026, every quarter from here is a financing quarter. The falsifiable clock is the next earnings release: investors should watch whether the Q3 2026 print shows subscription revenue continuing to grow at the H1 2026 pace, whether gross margin recovers above the 49 percent Q2 level once the one-time customer-success build-out normalizes, and whether the company draws the ATM facility or prices another private placement before cash falls below roughly six months of runway.